ZFIN ID: ZDB-FISH-150901-19390
Fish name: nl1Tg
Genotype: nl1Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by nl1Tg
No data available
GENE EXPRESSION
Gene expression in nl1Tg
RNA expression
Expressed Gene Structure Conditions Figures
anxa4 standard conditions Fig. 1 with image from Zhang et al., 2014
crx light ablation: photoreceptor cell Fig. 7 from Taylor et al., 2015
ctbp2a control Fig. 5 with image,  Fig. 6 with image from Sheets et al., 2011
ctbp2l control Fig. 5 with image,  Fig. s1 with image from Sheets et al., 2011
eif5a standard conditions Fig. 4 with image from Mastracci et al., 2015
elavl3 standard conditions Fig. 2 with image from Gao et al., 2015
fhl1b standard conditions Fig. 1 with image from Xu et al., 2016
chemical treatment by environment: DMH1 Fig. 1 with image from Xu et al., 2016
ins standard conditions Fig. 7 with image from Dash et al., 2016
Fig. 7 with image from Mastracci et al., 2015
Fig. 5 with image from Dalgin et al., 2011
chemical treatment by environment: DAPT Fig. 7 with image from Dash et al., 2016
isl1a standard conditions Fig. 3 with image from Wilfinger et al., 2013
isl2a standard conditions Fig. 3 with image from Wilfinger et al., 2013
isl2b standard conditions Fig. 3 with image from Wilfinger et al., 2013
lamp1b standard conditions Fig. 2 with image from Drerup et al., 2013
myo10l1 standard conditions Figure 7 with image from Tuttle et al., 2019
myod1 control Fig. 3 with image from Dalgin et al., 2011
neurod1 control Fig. 7 from Zecca et al., 2015
Fig. 3 with image from Dalgin et al., 2011
light ablation: photoreceptor cell Fig. 7 from Taylor et al., 2015
nkx6.1 control Fig. 3 with image from Zhang et al., 2017
chemical treatment by environment: LY-411575 Fig. 3 with image from Zhang et al., 2017
ret standard conditions Figure 1 with image from Tuttle et al., 2019
six1b standard conditions Fig. 3 from Mizoguchi et al., 2011
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-aldoc control Fig. 3 from Guissart et al., 2018
Ab1-tuba transection: posterior lateral line nerve Fig. 4 with image from Suli et al., 2016
Ab4-GFP transection: posterior lateral line nerve Fig. 4 with image from Suli et al., 2016
Ab4-GFP control Fig. 4 with image from Suli et al., 2016
Ab1-nsf standard conditions Fig. 2 with image from Mo et al., 2011
Ab2-ret standard conditions Figure 4 with image from Tuttle et al., 2019
Ab1-tuba control Fig. 4 with image from Suli et al., 2016
Ab1-gcg control Fig. 5 with image from Dalgin et al., 2011
Ab3-ctbp2l standard conditions Fig. 2 with image from Mo et al., 2011
Fig. 5 with image,  Fig. s1 with image from Sheets et al., 2011
Ab1-cyc standard conditions Fig. 2 with image from Drerup et al., 2017
Ab2-ctbp2l control Fig. 4 with image from Suli et al., 2016
Ab1-ret transection: axon: posterior lateral line ganglion Figure 5 with image from Tuttle et al., 2019
Ab1-myo10 standard conditions Figure 7 with image from Tuttle et al., 2019
Ab2-ret transection: axon: posterior lateral line ganglion Figure 5 with image from Tuttle et al., 2019
Ab1-ins standard conditions Fig. 3 with image from Kimmel et al., 2015
Fig. 5 with image from Dalgin et al., 2011
Ab1-ret standard conditions Figure 4 with image from Tuttle et al., 2019
Ab1-col2a standard conditions Fig. S4 with image from Culbertson et al., 2011
Ab15-mapk standard conditions Figure 4 supplement 1 with image from Tuttle et al., 2019
Fig. 2 with image,  Fig. 10 with image from Drerup et al., 2017
Fig. 3 with image from Drerup et al., 2013
Ab1-pvalb control Fig. 4 with image from Suli et al., 2016
Ab2-dync1h1 standard conditions Fig. 6 with image from Drerup et al., 2017
Ab1-dctn1 standard conditions Fig. 6 with image from Drerup et al., 2017
Ab1-pvalb transection: posterior lateral line nerve Fig. 4 with image from Suli et al., 2016
Ab1-lamp1 standard conditions Fig. 2 with image,  Fig. 10 with image from Drerup et al., 2017
Ab2-pcna light ablation: photoreceptor cell Fig. 7 from Taylor et al., 2015
Ab2-ctbp2l transection: posterior lateral line nerve Fig. 4 with image from Suli et al., 2016
Ab-2F11 anxa4 standard conditions Fig. 1 with image from Zhang et al., 2014
Fig. 3 with image,  Fig. 4 with image from Matsuda et al., 2013
Ab1-ctbp2a ctbp2a control Fig. 5 with image,  Fig. 6 with image from Sheets et al., 2011
Ab1-elavl elavl3 standard conditions Fig. 2 with image from Gao et al., 2015
Ab2-nkx6 nkx6.1 control Fig. 3 with image from Zhang et al., 2017
Ab2-nkx6 chemical treatment by environment: LY-411575 Fig. 3 with image from Zhang et al., 2017
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions 61 figures with image from 36 publications
chemical treatment: DAPT 14 figures with image from 12 publications
ablation: posterior lateral line nerve Fig. 7 from Taylor et al., 2015
Fig. 5 from Zecca et al., 2015
Fig. 8 with image,  Fig. 10 with image from Ceci et al., 2014
PHENOTYPE
Phenotype in nl1Tg
Phenotype Conditions Figures
anterior lateral line ganglion axon guidance process quality, abnormal light ablation: anterior lateral line ganglion, light ablation: statoacoustic (VIII) ganglion, chemical treatment by environment: leflunomide Fig. 5 from Zecca et al., 2015
cranial nerve VIII axon guidance process quality, abnormal light ablation: anterior lateral line ganglion, light ablation: statoacoustic (VIII) ganglion, chemical treatment by environment: leflunomide Fig. 5 from Zecca et al., 2015
endocrine pancreas EGFP expression decreased distribution, abnormal control Fig. S10 from O'Hare et al., 2016
endocrine pancreas development decreased process quality, abnormal chemical treatment by environment: DAPT Fig. 7 with image from Dash et al., 2016
exocrine pancreas nkx6.1 expression absent, abnormal chemical treatment by environment: LY-411575 Fig. 3 with image from Zhang et al., 2017
exocrine pancreas lacks all parts of type intrapancreatic duct, abnormal chemical treatment by environment: LY-411575 Fig. 3 with image from Zhang et al., 2017
exocrine pancreas development decreased process quality, abnormal chemical treatment by environment: LY-411575 Fig. 3 with image from Zhang et al., 2017
lateral line nerve axon terminus swollen, abnormal chemical treatment by environment: (aminomethyl)phosphonic acid Fig. 6 from Sebe et al., 2017
liver fhl1b expression decreased distribution, abnormal chemical treatment by environment: DMH1 Fig. 1 with image from Xu et al., 2016
myelinating Schwann cell absent, abnormal ablation: posterior lateral line nerve, chemical treatment: tyrphostin AG 1478 Fig. 8 with image from Ceci et al., 2014
neuromast hair cell synaptic ribbon decreased size, abnormal transection: posterior lateral line nerve Fig. 4 with image from Suli et al., 2016
neuromast hair cell synaptic ribbon increased amount, abnormal transection: posterior lateral line nerve Fig. 4 with image from Suli et al., 2016
neuromast hair cell synaptic ribbon mislocalised, abnormal transection: posterior lateral line nerve Fig. 4 with image from Suli et al., 2016
Notch signaling pathway decreased process quality, abnormal chemical treatment by environment: LY-411575 Fig. 3 with image from Zhang et al., 2017
pancreas has fewer parts of type secondary islet, abnormal chemical treatment: all-trans-retinoic acid Fig. S1 with image from Huang et al., 2014
pancreas posterior region has extra parts of type endocrine cell, abnormal chemical treatment: DAPT Fig. 6 with image from Kimmel et al., 2011
posterior lateral line ganglion axon truncated, abnormal chemical treatment by environment: sorafenib Figure 6 with image,  Figure 6 supplement 1 from Tuttle et al., 2019
posterior lateral line nerve defasciculated, abnormal ablation: posterior lateral line nerve, chemical treatment: tyrphostin AG 1478 Fig. 8 with image,  Fig. 10 with image from Ceci et al., 2014
posterior lateral line nerve axon guidance process quality, abnormal ablation: posterior lateral line nerve, chemical treatment: tyrphostin AG 1478 Fig. 8 with image,  Fig. 10 with image from Ceci et al., 2014
posterior lateral line nerve axon regeneration delayed, abnormal ablation: posterior lateral line nerve, chemical treatment: tyrphostin AG 1478 Fig. 10 with image from Ceci et al., 2014
posterior lateral line nerve axon regeneration process quality, abnormal ablation: posterior lateral line nerve, chemical treatment: tyrphostin AG 1478 Fig. 8 with image,  Fig. 10 with image from Ceci et al., 2014
primary islet EGFP expression increased amount, abnormal chemical treatment by environment: DAPT Fig. 7 with image from Dash et al., 2016
primary islet EGFP expression increased distribution, abnormal chemical treatment by environment: DAPT Fig. 7 with image from Dash et al., 2016
retinal inner nuclear layer cell population proliferation increased occurrence, abnormal chemical treatment: purpurogallin, chemical treatment: double-stranded DNA fragment Fig. 9 from Conner et al., 2014
retinal inner nuclear layer neuron differentiation increased occurrence, abnormal chemical treatment: purpurogallin, chemical treatment: double-stranded DNA fragment Fig. 9 from Conner et al., 2014
secondary islet cell increased amount, abnormal chemical treatment: 4-(diethylamino)benzaldehyde, chemical treatment: pharmaceutical Fig. 1 with image from Huang et al., 2014
secondary islet cell increased amount, abnormal chemical treatment: 4-(diethylamino)benzaldehyde Fig. 1 with image from Huang et al., 2014
secondary islet cell increased amount, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Huang et al., 2014
secondary islet endocrine pancreas development premature, abnormal chemical treatment: parthenolide Fig. 3 with image from Wang et al., 2015
statoacoustic (VIII) ganglion anatomical region decreased size, abnormal chemical treatment: SU5402 Fig. 3 from Wang et al., 2015

CITATIONS  (57)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.